

Josep M Argils

List of Publications by Year in Descending Order

Source: <https://exaly.com/author-pdf/9423451/josep-m-argiles-publications-by-year.pdf>

Version: 2024-04-28

This document has been generated based on the publications and citations recorded by exaly.com. For the latest version of this publication list, visit the link given above.

The third column is the impact factor (IF) of the journal, and the fourth column is the number of citations of the article.

190
papers

13,112
citations

60
h-index

109
g-index

195
ext. papers

14,854
ext. citations

5.8
avg, IF

6.14
L-index

#	Paper	IF	Citations
190	Lack of Synergy Between β Agonist Treatment and a Blockage of Sarcoplasmic Calcium Flow in a Rat Cancer Cachexia Model. <i>OncoTargets and Therapy</i> , 2021 , 14, 1953-1959	4.4	0
189	Differential structural features in soleus and gastrocnemius of carnitine-treated cancer cachectic rats. <i>Journal of Cellular Physiology</i> , 2020 , 235, 526-537	7	5
188	Autophagy Exacerbates Muscle Wasting in Cancer Cachexia and Impairs Mitochondrial Function. <i>Journal of Molecular Biology</i> , 2019 , 431, 2674-2686	6.5	41
187	Therapeutic strategies against cancer cachexia. <i>European Journal of Translational Myology</i> , 2019 , 29, 7960	2.1	27
186	Mediators of cachexia in cancer patients. <i>Nutrition</i> , 2019 , 66, 11-15	4.8	32
185	The animal cachexia score (ACASCO). <i>Animal Models and Experimental Medicine</i> , 2019 , 2, 201-209	4.2	3
184	Cancer cachexia, a clinical challenge. <i>Current Opinion in Oncology</i> , 2019 , 31, 286-290	4.2	12
183	Effects of the beta agonist formoterol on atrophy signaling, autophagy, and muscle phenotype in respiratory and limb muscles of rats with cancer-induced cachexia. <i>Biochimie</i> , 2018 , 149, 79-91	4.6	31
182	Inter-tissue communication in cancer cachexia. <i>Nature Reviews Endocrinology</i> , 2018 , 15, 9-20	15.2	97
181	Immobilization in diabetic rats results in altered glucose tolerance A model of reduced locomotion/activity in diabetes. <i>JCSM Rapid Communications</i> , 2018 , 1, 1-15	2.6	1
180	Omega-3 and omega-3/curcumin-enriched fruit juices decrease tumour growth and reduce muscle wasting in tumour-bearing mice. <i>JCSM Rapid Communications</i> , 2018 , 1, 1-10	2.6	2
179	The 2015 ESPEN Sir David Cuthbertson lecture: Inflammation as the driving force of muscle wasting in cancer. <i>Clinical Nutrition</i> , 2017 , 36, 798-803	5.9	14
178	Unifying diagnostic criteria for cachexia: An urgent need. <i>Clinical Nutrition</i> , 2017 , 36, 910-911	5.9	8
177	Novel targeted therapies for cancer cachexia. <i>Biochemical Journal</i> , 2017 , 474, 2663-2678	3.8	45
176	Validation of the CACHexia SCORe (CASCO). Staging Cancer Patients: The Use of miniCASCO as a Simplified Tool. <i>Frontiers in Physiology</i> , 2017 , 8, 92	4.6	28
175	A Rat Immobilization Model Based on Cage Volume Reduction: A Physiological Model for Bed Rest?. <i>Frontiers in Physiology</i> , 2017 , 8, 184	4.6	11
174	Formoterol attenuates increased oxidative stress and myosin protein loss in respiratory and limb muscles of cancer cachectic rats. <i>PeerJ</i> , 2017 , 5, e4109	3.1	15

173	Skeletal Muscle Regulates Metabolism via Interorgan Crosstalk: Roles in Health and Disease. <i>Journal of the American Medical Directors Association</i> , 2016 , 17, 789-96	5.9	199
172	Complete reversal of muscle wasting in experimental cancer cachexia: Additive effects of activin type II receptor inhibition and β agonist. <i>International Journal of Cancer</i> , 2016 , 138, 2021-9	7.5	44
171	Experimental cancer cachexia: Evolving strategies for getting closer to the human scenario. <i>Seminars in Cell and Developmental Biology</i> , 2016 , 54, 20-7	7.5	47
170	Conversion of leucine to β -hydroxy- β -methylbutyrate by β -keto isocaproate dioxygenase is required for a potent stimulation of protein synthesis in L6 rat myotubes. <i>Journal of Cachexia, Sarcopenia and Muscle</i> , 2016 , 7, 68-78	10.3	38
169	A multifactorial anti-cachectic approach for cancer cachexia in a rat model undergoing chemotherapy. <i>Journal of Cachexia, Sarcopenia and Muscle</i> , 2016 , 7, 48-59	10.3	37
168	Cachexia and sarcopenia: mechanisms and potential targets for intervention. <i>Current Opinion in Pharmacology</i> , 2015 , 22, 100-6	5.1	178
167	Open source in cachexia?. <i>Journal of Cachexia, Sarcopenia and Muscle</i> , 2015 , 6, 112-3	10.3	2
166	Muscle wasting in cancer: the role of mitochondria. <i>Current Opinion in Clinical Nutrition and Metabolic Care</i> , 2015 , 18, 221-5	3.8	46
165	Nonmuscle Tissues Contribution to Cancer Cachexia. <i>Mediators of Inflammation</i> , 2015 , 2015, 182872	4.3	36
164	Combination of exercise training and erythropoietin prevents cancer-induced muscle alterations. <i>Oncotarget</i> , 2015 , 6, 43202-15	3.3	63
163	Cachexia: a problem of energetic inefficiency. <i>Journal of Cachexia, Sarcopenia and Muscle</i> , 2014 , 5, 279-86	10.3	56
162	Hypothalamic food intake regulation in a cancer-cachectic mouse model. <i>Journal of Cachexia, Sarcopenia and Muscle</i> , 2014 , 5, 159-69	10.3	19
161	Cancer cachexia: understanding the molecular basis. <i>Nature Reviews Cancer</i> , 2014 , 14, 754-62	31.3	662
160	Formoterol in the treatment of experimental cancer cachexia: effects on heart function. <i>Journal of Cachexia, Sarcopenia and Muscle</i> , 2014 , 5, 315-20	10.3	33
159	Prevention of liver cancer cachexia-induced cardiac wasting and heart failure. <i>European Heart Journal</i> , 2014 , 35, 932-41	9.5	117
158	A differential pattern of gene expression in skeletal muscle of tumor-bearing rats reveals dysregulation of excitation-contraction coupling together with additional muscle alterations. <i>Muscle and Nerve</i> , 2014 , 49, 233-48	3.4	11
157	Distinct behaviour of sorafenib in experimental cachexia-inducing tumours: the role of STAT3. <i>PLoS ONE</i> , 2014 , 9, e113931	3.7	22
156	Recent Developments in Treatment of Cachexia. <i>AAPS Advances in the Pharmaceutical Sciences Series</i> , 2014 , 259-273	0.5	1

155	Cancer Cachexia 2013 ,		3
154	The potential of ghrelin in the treatment of cancer cachexia. <i>Expert Opinion on Biological Therapy</i> , 2013 , 13, 67-76	5.4	29
153	Mechanisms and treatment of cancer cachexia. <i>Nutrition, Metabolism and Cardiovascular Diseases</i> , 2013 , 23 Suppl 1, S19-24	4.5	36
152	A new look at an old drug for the treatment of cancer cachexia: megestrol acetate. <i>Clinical Nutrition</i> , 2013 , 32, 319-24	5.9	29
151	Mitochondrial and sarcoplasmic reticulum abnormalities in cancer cachexia: altered energetic efficiency?. <i>Biochimica Et Biophysica Acta - General Subjects</i> , 2013 , 1830, 2770-8	4	70
150	Skeletal muscle mitochondrial uncoupling in a murine cancer cachexia model. <i>International Journal of Oncology</i> , 2013 , 43, 886-94	4.4	71
149	Central melanin-concentrating hormone influences liver and adipose metabolism via specific hypothalamic nuclei and efferent autonomic/JNK1 pathways. <i>Gastroenterology</i> , 2013 , 144, 636-649.e6	13.3	64
148	Erythropoietin administration partially prevents adipose tissue loss in experimental cancer cachexia models. <i>Journal of Lipid Research</i> , 2013 , 54, 3045-51	6.3	13
147	Latest developments in cachexia drug discovery: clinical trials 2013 , 46-61		
146	Cancer cachexia 2013 , 2-5		
145	Myostatin: more than just a regulator of muscle mass. <i>Drug Discovery Today</i> , 2012 , 17, 702-9	8.8	85
144	Myostatin blockage using actRIIB antagonism in mice bearing the Lewis lung carcinoma results in the improvement of muscle wasting and physical performance. <i>Journal of Cachexia, Sarcopenia and Muscle</i> , 2012 , 3, 37-43	10.3	94
143	Megestrol acetate treatment influences tissue amino acid uptake and incorporation during cancer cachexia. <i>E-SPEN Journal</i> , 2012 , 7, e135-e138		3
142	Theophylline is able to partially revert cachexia in tumour-bearing rats. <i>Nutrition and Metabolism</i> , 2012 , 9, 76	4.6	13
141	L-Carnitine: an adequate supplement for a multi-targeted anti-wasting therapy in cancer. <i>Clinical Nutrition</i> , 2012 , 31, 889-95	5.9	29
140	Counteracting inflammation: a promising therapy in cachexia. <i>Critical Reviews in Oncogenesis</i> , 2012 , 17, 253-62	1.3	46
139	Inhibition of xanthine oxidase reduces wasting and improves outcome in a rat model of cancer cachexia. <i>International Journal of Cancer</i> , 2012 , 131, 2187-96	7.5	42
138	Are there any benefits of exercise training in cancer cachexia?. <i>Journal of Cachexia, Sarcopenia and Muscle</i> , 2012 , 3, 73-6	10.3	91

137	Formoterol treatment downregulates the myostatin system in skeletal muscle of cachectic tumour-bearing rats. <i>Oncology Letters</i> , 2012 , 3, 185-189	2.6	27
136	Formoterol and cancer muscle wasting in rats: Effects on muscle force and total physical activity. <i>Experimental and Therapeutic Medicine</i> , 2011 , 2, 731-735	2.1	13
135	Effects of eicosapentaenoic acid (EPA) treatment on insulin sensitivity in an animal model of diabetes: improvement of the inflammatory status. <i>Obesity</i> , 2011 , 19, 362-9	8	68
134	Nutraceutical inhibition of muscle proteolysis: a role of diallyl sulphide in the treatment of muscle wasting. <i>Clinical Nutrition</i> , 2011 , 30, 33-7	5.9	7
133	Anti-inflammatory therapies in cancer cachexia. <i>European Journal of Pharmacology</i> , 2011 , 668 Suppl 1, S81-6	5.3	55
132	Sirtuin 1 in skeletal muscle of cachectic tumour-bearing rats: a role in impaired regeneration?. <i>Journal of Cachexia, Sarcopenia and Muscle</i> , 2011 , 2, 57-62	10.3	21
131	The cachexia score (CASCO): a new tool for staging cachectic cancer patients. <i>Journal of Cachexia, Sarcopenia and Muscle</i> , 2011 , 2, 87-93	10.3	109
130	Combined approach to counteract experimental cancer cachexia: eicosapentaenoic acid and training exercise. <i>Journal of Cachexia, Sarcopenia and Muscle</i> , 2011 , 2, 95-104	10.3	63
129	Interleukin-15 affects differentiation and apoptosis in adipocytes: implications in obesity. <i>Lipids</i> , 2011 , 46, 1033-42	1.6	22
128	Effects of formoterol on protein metabolism in myotubes during hyperthermia. <i>Muscle and Nerve</i> , 2011 , 43, 268-73	3.4	5
127	Sarcopenia with limited mobility: an international consensus. <i>Journal of the American Medical Directors Association</i> , 2011 , 12, 403-9	5.9	648
126	Accounting Research: A Critical View Of The Present Situation And Prospects. <i>Revista De Contabilidad-Spanish Accounting Review</i> , 2011 , 14, 9-34	1.3	10
125	Fair value versus historical cost-based valuation for biological assets: predictability of financial information. <i>Revista De Contabilidad-Spanish Accounting Review</i> , 2011 , 14, 87-113	1.3	8
124	Nuclear magnetic resonance in conjunction with functional genomics suggests mitochondrial dysfunction in a murine model of cancer cachexia. <i>International Journal of Molecular Medicine</i> , 2011 , 27, 15-24	4.4	56
123	Muscle Wasting in Cancer and Ageing: Cachexia Versus Sarcopenia 2011 , 9-35		1
122	Cancer cachexia: physical activity and muscle force in tumour-bearing rats. <i>Oncology Reports</i> , 2011 , 25, 189-93	3.5	31
121	Optimal management of cancer anorexia-cachexia syndrome. <i>Cancer Management and Research</i> , 2010 , 2, 27-38	3.6	43
120	Redox balance and carbonylated proteins in limb and heart muscles of cachectic rats. <i>Antioxidants and Redox Signaling</i> , 2010 , 12, 365-80	8.4	62

119	Nutritional recommendations for the management of sarcopenia. <i>Journal of the American Medical Directors Association</i> , 2010 , 11, 391-6	5.9	387
118	Consensus definition of sarcopenia, cachexia and pre-cachexia: joint document elaborated by Special Interest Groups (SIG) "cachexia-anorexia in chronic wasting diseases" and "nutrition in geriatrics". <i>Clinical Nutrition</i> , 2010 , 29, 154-9	5.9	1075
117	Megestrol acetate: its impact on muscle protein metabolism supports its use in cancer cachexia. <i>Clinical Nutrition</i> , 2010 , 29, 733-7	5.9	21
116	Patterns of gene expression in muscle and fat in tumor-bearing rats: effects of CRF2R agonist on cachexia. <i>Muscle and Nerve</i> , 2010 , 42, 936-49	3.4	4
115	Oversecretion of interleukin-15 from skeletal muscle reduces adiposity. <i>American Journal of Physiology - Endocrinology and Metabolism</i> , 2009 , 296, E191-202	6	167
114	Therapeutic potential of interleukin-15: a myokine involved in muscle wasting and adiposity. <i>Drug Discovery Today</i> , 2009 , 14, 208-13	8.8	48
113	UCP3 overexpression neutralizes oxidative stress rather than nitrosative stress in mouse myotubes. <i>FEBS Letters</i> , 2009 , 583, 350-6	3.8	25
112	The role of cytokines in cancer cachexia. <i>Current Opinion in Supportive and Palliative Care</i> , 2009 , 3, 263-8	2.6	142
111	Interleukin-15 increases calcineurin expression in 3T3-L1 cells: possible involvement on in vivo adipocyte differentiation. <i>International Journal of Molecular Medicine</i> , 2009 , 24, 453-8	4.4	20
110	Both AP-1 and NF-kappaB seem to be involved in tumour growth in an experimental rat hepatoma. <i>Anticancer Research</i> , 2009 , 29, 1315-7	2.3	9
109	Effects of IL-15 on rat brown adipose tissue: uncoupling proteins and PPARs. <i>Obesity</i> , 2008 , 16, 285-9	8	35
108	Cachexia: a new definition. <i>Clinical Nutrition</i> , 2008 , 27, 793-9	5.9	1486
107	Novel approaches to the treatment of cachexia. <i>Drug Discovery Today</i> , 2008 , 13, 73-8	8.8	50
106	Apoptosis signalling is essential and precedes protein degradation in wasting skeletal muscle during catabolic conditions. <i>International Journal of Biochemistry and Cell Biology</i> , 2008 , 40, 1674-8	5.6	39
105	Effects of CRF2R agonist on tumor growth and cachexia in mice implanted with Lewis lung carcinoma cells. <i>Muscle and Nerve</i> , 2008 , 37, 190-5	3.4	17
104	Targets in clinical oncology: the metabolic environment of the patient. <i>Frontiers in Bioscience - Landmark</i> , 2007 , 12, 3024-51	2.8	15
103	Resveratrol does not ameliorate muscle wasting in different types of cancer cachexia models. <i>Clinical Nutrition</i> , 2007 , 26, 239-44	5.9	36
102	Protein breakdown on whole-body and organ level in non-cachectic tumour-bearing mice undergoing surgery. <i>Clinical Nutrition</i> , 2007 , 26, 483-90	5.9	7

101	Apoptosis is present in skeletal muscle of cachectic gastro-intestinal cancer patients. <i>Clinical Nutrition</i> , 2007 , 26, 614-8	5.9	54
100	Antiproteolytic effects of plasma from hibernating bears: a new approach for muscle wasting therapy?. <i>Clinical Nutrition</i> , 2007 , 26, 658-61	5.9	22
99	Potassium channels are a new target field in anticancer drug design. <i>Recent Patents on Anti-Cancer Drug Discovery</i> , 2007 , 2, 212-23	2.6	38
98	Are peroxisome proliferator-activated receptors involved in skeletal muscle wasting during experimental cancer cachexia? Role of beta2-adrenergic agonists. <i>Cancer Research</i> , 2007 , 67, 6512-9	10.1	38
97	Mechanisms to explain wasting of muscle and fat in cancer cachexia. <i>Current Opinion in Supportive and Palliative Care</i> , 2007 , 1, 293-8	2.6	38
96	Modulations of the calcineurin/NF-AT pathway in skeletal muscle atrophy. <i>Biochimica Et Biophysica Acta - General Subjects</i> , 2007 , 1770, 1028-36	4	6
95	Resveratrol, a natural diphenol, reduces metastatic growth in an experimental cancer model. <i>Cancer Letters</i> , 2007 , 245, 144-8	9.9	60
94	Emerging drugs for cancer cachexia. <i>Expert Opinion on Emerging Drugs</i> , 2007 , 12, 555-70	3.7	6
93	The AP-1/NF-kappaB double inhibitor SP100030 can revert muscle wasting during experimental cancer cachexia. <i>International Journal of Oncology</i> , 2007 , 30, 1239-45	1	14
92	Cytokines as mediators and targets for cancer cachexia. <i>Cancer Treatment and Research</i> , 2006 , 130, 199-217	3.7	44
91	Roles of skeletal muscle and peroxisome proliferator-activated receptors in the development and treatment of obesity. <i>Endocrine Reviews</i> , 2006 , 27, 318-29	27.2	28
90	IGF-1 is downregulated in experimental cancer cachexia. <i>American Journal of Physiology - Regulatory Integrative and Comparative Physiology</i> , 2006 , 291, R674-83	3.2	124
89	Training depletes muscle glutathione in patients with chronic obstructive pulmonary disease and low body mass index. <i>Respiration</i> , 2006 , 73, 757-61	3.7	46
88	Cancer Cachexia and Fat Metabolism 2006 , 459-466		2
87	The Role of Cytokines in Cancer Cachexia 2006 , 467-475		4
86	Interleukin-15 increases glucose uptake in skeletal muscle. An antidiabetogenic effect of the cytokine. <i>Biochimica Et Biophysica Acta - General Subjects</i> , 2006 , 1760, 1613-7	4	61
85	The AP-1/CJUN signaling cascade is involved in muscle differentiation: implications in muscle wasting during cancer cachexia. <i>FEBS Letters</i> , 2006 , 580, 691-6	3.8	23
84	Overexpression of UCP3 in both murine and human myotubes is linked with the activation of proteolytic systems: a role in muscle wasting?. <i>Biochimica Et Biophysica Acta - General Subjects</i> , 2006 , 1760, 253-8	4	13

83	Effects of interleukin-15 on lipid oxidation: disposal of an oral [(14)C]-triolein load. <i>Biochimica Et Biophysica Acta - Molecular and Cell Biology of Lipids</i> , 2006 , 1761, 37-42	5	43
82	Molecular mechanisms involved in muscle wasting in cancer and ageing: cachexia versus sarcopenia. <i>International Journal of Biochemistry and Cell Biology</i> , 2005 , 37, 1084-104	5.6	118
81	The pivotal role of cytokines in muscle wasting during cancer. <i>International Journal of Biochemistry and Cell Biology</i> , 2005 , 37, 1609-19	5.6	35
80	The pivotal role of cytokines in muscle wasting during cancer. <i>International Journal of Biochemistry and Cell Biology</i> , 2005 , 37, 2036-46	5.6	75
79	Activation of UCPs gene expression in skeletal muscle can be independent on both circulating fatty acids and food intake. Involvement of ROS in a model of mouse cancer cachexia. <i>FEBS Letters</i> , 2005 , 579, 717-22	3.8	45
78	Both oxidative and nitrosative stress are associated with muscle wasting in tumour-bearing rats. <i>FEBS Letters</i> , 2005 , 579, 1646-52	3.8	93
77	Interleukin-15 stimulates adiponectin secretion by 3T3-L1 adipocytes: evidence for a skeletal muscle-to-fat signaling pathway. <i>Cell Biology International</i> , 2005 , 29, 449-57	4.5	126
76	Mediators involved in the cancer anorexia-cachexia syndrome: past, present, and future. <i>Nutrition</i> , 2005 , 21, 977-85	4.8	73
75	Cross-talk between skeletal muscle and adipose tissue: a link with obesity?. <i>Medicinal Research Reviews</i> , 2005 , 25, 49-65	14.4	132
74	Cross-Talk Between Skeletal Muscle and Adipose Tissue: A Link with Obesity?. <i>ChemInform</i> , 2005 , 36, no		1
73	Interleukin-15 decreases lipid intestinal absorption. <i>International Journal of Molecular Medicine</i> , 2005 , 15, 963-7	4.4	7
72	Systemic inflammation correlates with increased expression of skeletal muscle ubiquitin but not uncoupling proteins in cancer cachexia. <i>Oncology Reports</i> , 2005 , 14, 257-63	3.5	58
71	Interleukin-15 decreases proteolysis in skeletal muscle: a direct effect. <i>International Journal of Molecular Medicine</i> , 2005 , 16, 471-6	4.4	50
70	Effect of c-ski overexpression on the development of cachexia in mice bearing the Lewis lung carcinoma.. <i>International Journal of Molecular Medicine</i> , 2004 , 14, 719	4.4	1
69	The pharmacological treatment of cachexia. <i>Current Drug Targets</i> , 2004 , 5, 265-77	3	39
68	Anticachectic effects of formoterol: a drug for potential treatment of muscle wasting. <i>Cancer Research</i> , 2004 , 64, 6725-31	10.1	131
67	Interleukin-15 is able to suppress the increased DNA fragmentation associated with muscle wasting in tumour-bearing rats. <i>FEBS Letters</i> , 2004 , 569, 201-6	3.8	81
66	The systemic inflammatory response is involved in the regulation of K(+) channel expression in brain via TNF-alpha-dependent and -independent pathways. <i>FEBS Letters</i> , 2004 , 572, 189-94	3.8	21

65	Rat liver lipogenesis is modulated by interleukin-15. <i>International Journal of Molecular Medicine</i> , 2004 , 13, 817-9	4.4	13
64	The use of financial accounting information and firm performance: an empirical quantification for farms. <i>Accounting and Business Research</i> , 2003 , 33, 251-273	1.9	28
63	Cytokines in the pathogenesis of cancer cachexia. <i>Current Opinion in Clinical Nutrition and Metabolic Care</i> , 2003 , 6, 401-6	3.8	93
62	Catabolic mediators as targets for cancer cachexia. <i>Drug Discovery Today</i> , 2003 , 8, 838-44	8.8	38
61	Impaired voltage-gated K ⁺ channel expression in brain during experimental cancer cachexia. <i>FEBS Letters</i> , 2003 , 536, 45-50	3.8	16
60	Reduced protein degradation rates and low expression of proteolytic systems support skeletal muscle hypertrophy in transgenic mice overexpressing the c-ski oncogene. <i>Cancer Letters</i> , 2003 , 200, 153-60	9.9	16
59	Cancer cachexia: the molecular mechanisms. <i>International Journal of Biochemistry and Cell Biology</i> , 2003 , 35, 405-9	5.6	85
58	Tumour necrosis factor-alpha uncouples respiration in isolated rat mitochondria. <i>Cytokine</i> , 2003 , 22, 1-4	4	36
57	Increased tumour necrosis factor-alpha plasma levels during moderate-intensity exercise in COPD patients. <i>European Respiratory Journal</i> , 2003 , 21, 789-94	13.6	123
56	Sepsis induces DNA fragmentation in rat skeletal muscle. <i>European Cytokine Network</i> , 2003 , 14, 256-9	3.3	10
55	Tumor necrosis factor-alpha exerts interleukin-6-dependent and -independent effects on cultured skeletal muscle cells. <i>Biochimica Et Biophysica Acta - Molecular Cell Research</i> , 2002 , 1542, 66-72	4.9	52
54	Branched-chain amino acids: a role in skeletal muscle proteolysis in catabolic states?. <i>Journal of Cellular Physiology</i> , 2002 , 191, 283-9	7	35
53	Les facteurs cataboliques du cancer : données récentes. <i>Nutrition Clinique Et Metabolisme</i> , 2002 , 16, 14-25	0.8	2
52	Overexpression of interleukin-15 induces skeletal muscle hypertrophy in vitro: implications for treatment of muscle wasting disorders. <i>Experimental Cell Research</i> , 2002 , 280, 55-63	4.2	158
51	The role of uncoupling proteins in pathophysiological states. <i>Biochemical and Biophysical Research Communications</i> , 2002 , 293, 1145-52	3.4	80
50	Effects of interleukin-15 (IL-15) on adipose tissue mass in rodent obesity models: evidence for direct IL-15 action on adipose tissue. <i>Biochimica Et Biophysica Acta - General Subjects</i> , 2002 , 1570, 33-7	4	73
49	TNF-alpha modulates cytokine and cytokine receptors in C2C12 myotubes. <i>Cancer Letters</i> , 2002 , 175, 181-5	9.9	30
48	Effects of the phosphodiesterase-IV inhibitor EMD 95832/3 on tumour growth and cachexia in rats bearing the Yoshida AH-130 ascites hepatoma. <i>Cancer Letters</i> , 2002 , 188, 53-8	9.9	1

47	Accounting information and the prediction of farm non-viability. <i>European Accounting Review</i> , 2001 , 10, 73-105	2.1	32
46	Reduced muscle redox capacity after endurance training in patients with chronic obstructive pulmonary disease. <i>American Journal of Respiratory and Critical Care Medicine</i> , 2001 , 164, 1114-8	10.2	132
45	Interleukin-15 mediates reciprocal regulation of adipose and muscle mass: a potential role in body weight control. <i>Biochimica Et Biophysica Acta - General Subjects</i> , 2001 , 1526, 17-24	4	128
44	Curcumin, a natural product present in turmeric, decreases tumor growth but does not behave as an anticachectic compound in a rat model. <i>Cancer Letters</i> , 2001 , 167, 33-8	9.9	76
43	Increased uncoupling protein-2 gene expression in brain of lipopolysaccharide-injected mice: role of tumour necrosis factor-alpha?. <i>Biochimica Et Biophysica Acta - Molecular Cell Research</i> , 2001 , 1499, 249-56	4.9	21
42	Hyperlipemia: a role in regulating UCP3 gene expression in skeletal muscle during cancer cachexia?. <i>FEBS Letters</i> , 2001 , 505, 255-8	3.8	28
41	Metabolic interrelationships between liver and skeletal muscle in pathological states. <i>Life Sciences</i> , 2001 , 69, 1345-61	6.8	15
40	Branched-chain amino acids inhibit proteolysis in rat skeletal muscle: mechanisms involved. <i>Journal of Cellular Physiology</i> , 2000 , 184, 380-4	7	53
39	Short-term effects of leptin on skeletal muscle protein metabolism in the rat. <i>Journal of Nutritional Biochemistry</i> , 2000 , 11, 431-5	6.3	30
38	DNA fragmentation occurs in skeletal muscle during tumor growth: A link with cancer cachexia?. <i>Biochemical and Biophysical Research Communications</i> , 2000 , 270, 533-7	3.4	87
37	The role of cytokines in cancer cachexia. <i>Medicinal Research Reviews</i> , 1999 , 19, 223-48	14.4	154
36	Leptin and tumor growth in rats. <i>International Journal of Cancer</i> , 1999 , 81, 726-9	7.5	36
35	Resveratrol, a natural product present in wine, decreases tumour growth in a rat tumour model. <i>Biochemical and Biophysical Research Communications</i> , 1999 , 254, 739-43	3.4	220
34	Role of TNF receptor 1 in protein turnover during cancer cachexia using gene knockout mice. <i>Molecular and Cellular Endocrinology</i> , 1998 , 142, 183-9	4.4	94
33	Protein turnover in skeletal muscle of tumour-bearing transgenic mice overexpressing the soluble TNF receptor-1. <i>Cancer Letters</i> , 1998 , 130, 19-27	9.9	63
32	Different cytokines modulate ubiquitin gene expression in rat skeletal muscle. <i>Cancer Letters</i> , 1998 , 133, 83-7	9.9	92
31	Short-term effects of leptin on lipid metabolism in the rat. <i>FEBS Letters</i> , 1998 , 431, 371-4	3.8	23
30	Skeletal muscle UCP2 and UCP3 gene expression in a rat cancer cachexia model. <i>FEBS Letters</i> , 1998 , 436, 415-8	3.8	60

29	In the rat, tumor necrosis factor alpha administration results in an increase in both UCP2 and UCP3 mRNAs in skeletal muscle: a possible mechanism for cytokine-induced thermogenesis?. <i>FEBS Letters</i> , 1998 , 440, 348-50	3.8	80
28	Catabolic proinflammatory cytokines. <i>Current Opinion in Clinical Nutrition and Metabolic Care</i> , 1998 , 1, 245-51	3.8	50
27	Is TNF really involved in cachexia?. <i>Cancer Investigation</i> , 1997 , 15, 47-54	2.1	22
26	TNF can directly induce the expression of ubiquitin-dependent proteolytic system in rat soleus muscles. <i>Biochemical and Biophysical Research Communications</i> , 1997 , 230, 238-41	3.4	143
25	Lipid metabolism in tumour-bearing mice: studies with knockout mice for tumour necrosis factor receptor 1 protein. <i>Molecular and Cellular Endocrinology</i> , 1997 , 132, 93-9	4.4	25
24	Sequential changes in lipoprotein lipase activity and lipaemia induced by the Yoshida AH-130 ascites hepatoma in rats. <i>Cancer Letters</i> , 1997 , 116, 159-65	9.9	10
23	Comparative effects of beta2-adrenergic agonists on muscle waste associated with tumour growth. <i>Cancer Letters</i> , 1997 , 115, 113-8	9.9	42
22	Journey from cachexia to obesity by TNF. <i>FASEB Journal</i> , 1997 , 11, 743-51	0.9	111
21	The ubiquitin system: a role in disease?. <i>Medicinal Research Reviews</i> , 1997 , 17, 139-61	14.4	6
20	The metabolic basis of cancer cachexia. <i>Medicinal Research Reviews</i> , 1997 , 17, 477-98	14.4	131
19	The ubiquitin-dependent proteolytic pathway in skeletal muscle: its role in pathological states. <i>Trends in Pharmacological Sciences</i> , 1996 , 17, 223-6	13.2	63
18	Muscle hypercatabolism during cancer cachexia is not reversed by the glucocorticoid receptor antagonist RU38486. <i>Cancer Letters</i> , 1996 , 99, 7-14	9.9	28
17	Lipid metabolism in rats bearing the Yoshida AH-130 ascites hepatoma. <i>Molecular and Cellular Biochemistry</i> , 1996 , 165, 17-23	4.2	16
16	Metabolic effects of tumour necrosis factor-alpha on rat brown adipose tissue. <i>Molecular and Cellular Biochemistry</i> , 1995 , 143, 113-8	4.2	10
15	Lipopolysaccharide (LPS) increases the in vivo oxidation of branched-chain amino acids in the rat: a cytokine-mediated effect. <i>Molecular and Cellular Biochemistry</i> , 1995 , 148, 9-15	4.2	17
14	Enhanced leucine oxidation in rats bearing an ascites hepatoma (Yoshida AH-130) and its reversal by clenbuterol. <i>Cancer Letters</i> , 1995 , 91, 73-8	9.9	24
13	Interleukin-1 receptor antagonist (IL-1ra) is unable to reverse cachexia in rats bearing an ascites hepatoma (Yoshida AH-130). <i>Cancer Letters</i> , 1995 , 95, 33-8	9.9	45
12	Lack of effect of eicosapentaenoic acid in preventing cancer cachexia and inhibiting tumor growth. <i>Cancer Letters</i> , 1995 , 97, 25-32	9.9	21

11	Marked hyperlipidaemia in rats bearing the Yoshida AH-130 ascites hepatoma. <i>Biochemical Society Transactions</i> , 1995 , 23, 492S	5.1	2
10	Muscle wasting associated with cancer cachexia is linked to an important activation of the ATP-dependent ubiquitin-mediated proteolysis. <i>International Journal of Cancer</i> , 1995 , 61, 138-41	7.5	98
9	Interleukin-6 does not activate protein breakdown in rat skeletal muscle. <i>Cancer Letters</i> , 1994 , 76, 1-4	9.9	43
8	Alanine metabolism in rats bearing the Yoshida AH-130 ascites hepatoma. <i>Cancer Letters</i> , 1994 , 87, 123-30	3.9	9
7	Ubiquitin gene expression is increased in skeletal muscle of tumour-bearing rats. <i>FEBS Letters</i> , 1994 , 338, 311-8	3.8	107
6	Anti-tumour necrosis factor-alpha treatment interferes with changes in lipid metabolism in a tumour cachexia model. <i>Clinical Science</i> , 1994 , 87, 349-55	6.5	66
5	A flow cytometric study of the rat Yoshida AH-130 ascites hepatoma. <i>Cancer Letters</i> , 1993 , 72, 169-73	9.9	13
4	Tumour necrosis factor-alpha increases the ubiquitination of rat skeletal muscle proteins. <i>FEBS Letters</i> , 1993 , 323, 211-4	3.8	116
3	The role of cytokines in muscle wasting: its relation with cancer cachexia. <i>Medicinal Research Reviews</i> , 1992 , 12, 637-52	14.4	74
2	Metabolic effects of tumour necrosis factor-alpha (cachectin) and interleukin-1. <i>Clinical Science</i> , 1989 , 77, 357-64	6.5	123
1	Formoterol May Activate Rat Muscle Regeneration During Cancer Cachexia. <i>Insciences Journal</i> , 1-17		8